How long is alectinib effective?

Alectinib Induces a Durable (>15 Months) Complete Response in an ALK-Positive Non-Small Cell Lung Cancer Patient Who Progressed on Crizotinib With Diffuse Leptomeningeal Carcinomatosis.

What type of drug is alectinib?

Alectinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply.

Is alectinib a targeted therapy?

Alectinib is a targeted therapy. It is a tyrosine kinase inhibitor (TKI). Tyrosine kinases are specific enzymes (a type of protein) that may signal cancer cells to grow. TKI’s block these cell signals and by blocking the signals, they stop the growth of the cancer cells.

Does alectinib cross the blood brain barrier?

Pre-clinical studies have demonstrated that alectinib has a high penetration in the brain and is not transported by the P-glycoprotein efflux transporter, which is a key factor for maintaining the blood-brain barrier (11).

Can Alectinib shrink tumors?

ALECENSA was able to shrink the size of tumors in nearly 80% of people with ALK+ mNSCLC.

Is the ALK gene hereditary?

Is it hereditary? The ALK mutation isn’t inherited like the BRCA mutations that cause breast cancer. This gene change happens during your lifetime.

Does everyone have the ALK gene?

Everyone has two copies of the ALK gene, which we randomly inherit from each of our parents. Mutations in one copy of the ALK gene can increase the chance for you to develop certain types of cancer and/or non-cancerous tumors in your lifetime.

Is crizotinib or alectinib better for lung cancer?

Alectinib in terms of overall response rate, progression-free survival and partial response is superior to crizotinib in the treatment of ALK-positive non-small cell lung cancer and is well tolerated. Compared with crizotinib, alectinib is more effective than crizotinib and has a lower incidence of total adverse reactions.

Is alectinib a first-line treatment for alkinhibitors in non-small cell lung cancer?

Compared with crizotinib, alectinib is more effective than crizotinib and has a lower incidence of total adverse reactions. Meta-analysis results confirm the strong base for alectinib as a first-line treatment for ALK-positive NSCLC. Keywords: alectinib, crizotinib, ALKinhibitors, non-small cell lung cancer, efficacy and safety Introduction

What is the total response rate for Crizotinib and alectinib?

Three studies reported total response rates, There were 380 patients in alectinib and 317 patients in the crizotinib, The study indicates very low statistical heterogeneity (P = 0.38, I2= 0%), Due to low heterogeneity among the studies, the fixed effect model was used for Meta-analysis.

Is crizotinib more effective than chemotherapy for anaplastic lymphoma kinase (ALK) positive advanced NSCLC?

In recent years, a meta-analysis result showed that crizotinib is more effective than chemotherapy in treating anaplastic lymphoma kinase (ALK) positive advanced NSCLC (9). Crizotinib is ALK’s first small molecule inhibitor and was approved in the US in 2011 for the treatment of patients with ALK-positive advanced NSCLC (10).